Skip to main content

Further pharma buys for Aceto

21st May 2021

Submitted by:

Andrew Warmington

Speciality life science materials player Aceto has made two further acquisitions, both in the pharmaceutical field, in the form of Oregon-based Cascade Chemistry and Finar in India. Terms were not disclosed in either case.

These bring the total number of acquisitions the new-look firm has made to five in the past 15 months. “With each of our acquisitions, Aceto looks to add companies that enhance our business capabilities and support our growth strategy, while aligning with our core business values,” said CEO Gilles Cottier.

Cascade is a CDMO that makes APIs, regulatory starting materials and advanced intermediates with services in synthetic route optimisation, process development and scale up. It claims differentiated expertise in producing alkaloids, heterocycles, steroids, terpenes, prostaglandins, phenylacetylenes and chiral syntheses.

Prior to being acquired, Cascade had announced the construction of new facilities, which will triple manufacturing capacity for APIs for clinical trials and ultimately commercial production. This is expected to be operational in 2022.

Based at Ahmedabad, India, and active in 50 national markets, Finar makes pharmaceutical ingredients including GMP and pharmaceutical- grade solvents, advanced intermediates and GMP excipients, as well as laboratory chemicals, aquaculture inputs and food grade additives. Aceto said that it will continue to support Finar’s facilities and offices.

All this followed shortly on from the acquisition in April of A&C, which brought sites in North America to the biopharma and cell culture portfolio, which includes nucleotides, nucleosides, bio-buffers and cell culture media ingredients like amino acids and vitamins. Aceto was already active in this field via Pharma Waldhof in Germany, where it has just expanded the portfolio.

In December 2020, Aceto had announced the acquisition of IsleChem in Grand Island, New York, whose core business includes chemical manufacturing, contract R&D, analytical services, and technical and support services. This brought in US-based supply to add to the existing supply network focused on India and China. Further expansion is planned at the IsleChem site.

Previously, in April 2020, Aceto had acquired Syntor Fine Chemicals, a UK-based, largely virtual manufacturer of fine chemicals for pharmaceutical and other life sciences markets. This brought it additional synthesis and formulation capabilities, together with greater product customisation, the company said at the time. 

Feature article – Saltigo rides out the cycle

Market and sustainability trends are positive drivers for Saltigo, despite the agro downturn. Andrew Warmington met up with the new CEO at Chemspec Europe

Submitted by:

Andrew Warmington

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical active ingredient (AI) manufacturing to its wholly owned subsidiary UPL Spec

Submitted by:

Andrew Warmington

Nippon Shokubai opens Indonesian plant

Japan’s Nippon Shokubai has officially opened a 100,000 tonnes/year acrylic acid (AA) plant that was built at a cost of about $200 million at Cilegon, Banten, Indonesia.

Submitted by:

Andrew Warmington

CABB to invest at Finnish agro site

The CABB Group has said that it will invest over €50 million by 2025 to expand facilities at its agrochemical manufacturing site in Kokkola, Finland.

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production planning of superabsorbent polymers (SAPs) based on acrylic acid, and has started operati

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after a week after the latter declined to engage with it.

Submitted by:

Andrew Warmington

adcs

Three invest further into ADCs

Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.

Submitted by:

Andrew Warmington

Cambrex exits drug product

CDMO Cambrex has sold its Drug Product business unit to Noramco. Terms were not disclosed.

Submitted by:

Andrew Warmington

Siegfried breaks ground on R&D centre

Siegfried has broke ground for its new global R&D centre for drug substances at its site in Evionnaz, Switzerland.

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants under the trade names AmphiCare and AmphiClean.

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based subsidiary of Seqens.

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in Austria have co-developed a computer-assisted regression model to improve enzyme performance and

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU and the Bio-based Industries Consortium (BIC) that funds projects advancing competitive circular bi

Submitted by:

Andrew Warmington

Investment in Tanasote plant

Octowood, a part of the Sweden’s Rundvirke Industrier Group, has invested in a new treatment plant using Arxada’s wood preservative, Tanasote.

Submitted by:

Andrew Warmington

Rhamnolipid milestone reached

Evonik has manufactured the first product from its industrial-scale biosurfactants facility at Slovenská Lupca in Slovakia.

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach Group in a move that it said would “create a global pigment company, combining SCIL’s ope

Submitted by:

Andrew Warmington

Lanxess to continue pigment production

Lanxess has reversed a decision to sell the chromium oxide pigments business at the Krefeld-Uerdingen site in Germany, preserving 50 jobs there.

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw materials, has announced a strategic collaboration with Japan’s Takasago, a large player in th

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site in Guangzhou. This triples its manufacturing capacity for fragrances and establis

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable fragrance ingredients from renewable carbon, with US-based LanzaTech, which describes i

Submitted by:

Andrew Warmington

Kao boosts jasmine fragrance

Japan's Kao Corporation is to double capacity for the synthetic fragrance methyl dihydrojasmonate (MDJ) at its site in Olesa, Spain, by adding a second production facility.

Submitted by:

Andrew Warmington

Merck KGaA “in a strong strategic position”

At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitio

Submitted by:

Andrew Warmington

Suez joins Global Impact Coalition

Suez, which describes itself as “a global leader in circular solutions for water and waste”, has joined the Global Impact Coalition (GIC).

Submitted by:

Andrew Warmington

Chemours opens battery lab

Chemours has opened Chemours Battery Innovation Centre (CBIC) at the Chemours Discovery Hub in Newark, Delaware.

Submitted by:

Andrew Warmington